Search for 'Provider:Haematologica, and itype:ART'

Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation.

By Ayala Díaz, Rosa María. Haematologica, 2016 . 101(8):926-31. , Formato Vancouver: Alvarez Larrán A, Pereira A, Guglielmelli P, Hernández Boluda JC, Arellano Rodrigo E, Ferrer Marín F et al. Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation. Haematologica. 2016 Aug;101(8):926-31.

Place Hold on Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation.

Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma.

By Martínez López, Joaquín. Haematologica, 2016 . 101(7):872-8. , Formato Vancouver: Weisel KC, Dimopoulos MA, Moreau P, Lacy MQ, Song KW, Delforge M et al. Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma. Haematologica. 2016 Jul;101(7):872-8.

Place Hold on Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma.

The syndrome of hemophagocytic lymphohistiocytosis in primary immunodeficiencies: implications for differential diagnosis and pathogenesis.

By González Granados, Luis Ignacio. Haematologíca, 2015 . 100(7):978-88. , Formato Vancouver: Bode SF, Ammann S, Al-Herz W, Bataneant M, Dvorak CC, Gehring S et al; Inborn Errors Working Party of the EBMT. The syndrome of hemophagocytic lymphohistiocytosis in primary immunodeficiencies: implications for differential diagnosis and pathogenesis. Haematologica. 2015 Jul;100(7):978-88.

Place Hold on The syndrome of hemophagocytic lymphohistiocytosis in primary immunodeficiencies: implications for differential diagnosis and pathogenesis.

Recurrent presence of the PLCG1 S345F mutation in nodal peripheral T-cell lymphomas.

By Rodríguez Peralto, José Luis. Haematologica, 2015 . 100(1):e25-7. , Formato Vancouver: Manso R, Rodríguez Pinilla SM, González Rincón J, Gómez S, Monsalvo S, Llamas P et al. Recurrent presence of the PLCG1 S345F mutation in nodal peripheral T-cell lymphomas. Haematologica. 2015 Jan;100(1):e25-7.

Place Hold on Recurrent presence of the PLCG1 S345F mutation in nodal peripheral T-cell lymphomas.

Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: phase Ib/II panobidara study.

By Castro Quismondo, Nerea. Haematologica, 2015 . 100(10):1294-300. , Formato Vancouver: Ocio EM, Herrera P, Olave MT, Castro N, Pérez Simón JA, Brunet S et al; PETHEMA Group. Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: phase Ib/II panobidara study. Haematologica. 2015 Oct;100(10):1294-300.

Place Hold on Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: phase Ib/II panobidara study.

Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma.

By Martínez López, Joaquín. Haematologica, 2015 . 100(10):1334-9. , Formato Vancouver: San Miguel JF, Weisel KC, Song KW, Delforge M, Karlin L, Goldschmidt H et al. Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma. Haematologica. 2015 Oct;100(10):1334-9.

Place Hold on Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma.

Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone.

By Martínez López, Joaquín. Haematologica, 2015 . 100(10):1327-33. , Formato Vancouver Dimopoulos MA, Weisel KC, Song KW, Delforge M, Karlin L, Goldschmidt H et al. Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone. Haematologica. 2015 Oct;100(10):1327-33.

Place Hold on Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone.

Bendamustine, bortezomib and prednisone for the treatment of patients with newly diagnosed multiple myeloma: results of a prospective phase 2 Spanish/PETHEMA trial.

By Martínez López, Joaquín. Haematologica, 2015 . 1096-102. , Formato Vancouver: Mateos MV, Oriol A, Rosiñol L, de Arriba F, Puig N, Martín J et al. Bendamustine, bortezomib and prednisone for the treatment of patients with newly diagnosed multiple myeloma: results of a prospective phase 2 Spanish/PETHEMA trial. Haematologica. 2015 Aug;100(8):1096-102.

Place Hold on Bendamustine, bortezomib and prednisone for the treatment of patients with newly diagnosed multiple myeloma: results of a prospective phase 2 Spanish/PETHEMA trial.

Transcriptome analysis reveals molecular profiles associated with evolving steps of monoclonal gammopathies.

By Lahuerta Palacios, Juan José . Haematologica, 2014 . 99(8):1365-72. , Formato Vancouver: López Corral L, Corchete LA, Sarasquete ME, Mateos MV, García Sanz R, Fermiñán E et al. Transcriptome analysis reveals molecular profiles associated with evolving steps of monoclonal gammopathies. Haematologica. 2014 Aug;99(8):1365-72.

Place Hold on Transcriptome analysis reveals molecular profiles associated with evolving steps of monoclonal gammopathies.

Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan plus BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial.

By Grande García, Carlos. Haematologica, 2014 . 99(3):505-10. , Formato Vancouver: Briones J, Novelli S, García-Marco JA, Tomás JF, Bernal T, Grande C et al. GELTAMO. Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan plus BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial. Haematologica. 2014 Mar;99(3):505-10.

Place Hold on Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan plus BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial.

Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy.

By Lahuerta Palacios, Juan José . Haematologica, 2014 . 99(6):1114-22. , Formato Vancouver: Mateos MV, Bringhen S, Richardson PG, Lahuerta JJ, Larocca A, Oriol A et al. Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy. Haematologica. 2014 Jun;99(6):1114-22.

Place Hold on Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy.

Simultaneous inhibition of pan-phosphatidylinositol-3-kinases and MEK as a potential therapeutic strategy in peripheral T-cell lymphomas.

By Ortiz Romero, Pablo Luis | Rodríguez Peralto, José Luis. Haematologica, 2013 . 98(1):57-64. , Formato Vancouver: Martín-Sánchez E, Rodríguez-Pinilla SM, Sánchez-Beato M, Lombardía L, Domínguez-González B, Romero D et al. Simultaneous inhibition of pan-phosphatidylinositol-3-kinases and MEK as a potential therapeutic strategy in peripheral T-cell lymphomas. Haematologica. 2013 Jan;98(1):57-64.

Place Hold on Simultaneous inhibition of pan-phosphatidylinositol-3-kinases and MEK as a potential therapeutic strategy in peripheral T-cell lymphomas.

Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry.

By Lahuerta Palacios, Juan José | Martínez López, Joaquín. Haematologica, 2013 . 98(1):79-86. , Formato Vancouver: Pessoa de Magalhães RJ, Vidriales MB, Paiva B, Fernández-Giménez C, García-Sanz R, Mateos MV et al. Spanish Myeloma Group (GEM); Grupo Castellano-Leones de Gammapatias Monoclonales, cooperative study groups. Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry. Haematologica. 2013 Jan;98(1):79-86.

Place Hold on Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry.

Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials.

By Lahuerta Palacios, Juan José . Haematologica, 2013 . 98(6):980-7. , Formato Vancouver: Bringhen S, Mateos MV, Zweegman S, Larocca A, Falcone AP, Oriol A et al. Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials. Haematologica. 2013 Jun;98(6):980-7.

Place Hold on Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials.

First-line treatment with rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine and followed by consolidation with Y-90-ibritumomab-tiuxetan in patients with mantle cell lymphoma. Results of a multicenter, phase 2 pilot trial from the GELTAMO group.

By Grande García, Carlos | Martínez Sánchez, María Pilar. Haematologica, 2013 . 98(10):1563-70. , Formato Vancouver: Arranz R, García-Noblejas A, Grande C, Cannata-Ortiz J, Sánchez JJ, García-Marco JA et al. First-line treatment with rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine and followed by consolidation with 90Y-ibritumomab-tiuxetan in patients with mantle cell lymphoma. Results of a multicenter, phase 2 pilot trial from the GELTAMO group. Haematologica. 2013 Oct;98(10):1563-70.

Place Hold on First-line treatment with rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine and followed by consolidation with Y-90-ibritumomab-tiuxetan in patients with mantle cell lymphoma. Results of a multicenter, phase 2 pilot trial from the GELTAMO group.

Genomic analysis of high-risk smoldering multiple myeloma.

By Lahuerta Palacios, Juan José . Haematologica, 2012 . 97(9):1439-43. , Formato Vancouver: López-Corral L, Mateos MV, Corchete LA, Sarasquete ME, de la Rubia J, de Arriba F, et al. Genomic analysis of high-risk smoldering multiple myeloma. Haematologica. 2012 Sep;97(9):1439-43.

Place Hold on Genomic analysis of high-risk smoldering multiple myeloma.

Benefit from autologous stem cell transplantation in primary refractory myeloma? Different outcomes in progressive versus stable disease.

By Lahuerta Palacios, Juan José . Haematologica, 2012 . 97(4):616-21. , Formato Vancouver: Rosiñol L, García-Sanz R, Lahuerta JJ, Hernández-García M, Granell M, de la Rubia J, et al. Benefit from autologous stem cell transplantation in primary refractory myeloma? Different outcomes in progressive versus stable disease. Haematologica. 2012 Apr;97(4):616-21.

Place Hold on Benefit from autologous stem cell transplantation in primary refractory myeloma? Different outcomes in progressive versus stable disease.

Natural killer cell lines preferentially kill clonogenic multiple myeloma cells and decrease myeloma engraftment in a bioluminescent xenograft mouse model

By Martínez López, Joaquín. Haematologica, 2012 . 97(7):1020-1028. , Formato Vancouver: Swift BE, Williams BA, Kosaka Y, Wang XH, Medin JA, Viswanathan S, et al. Natural killer cell lines preferentially kill clonogenic multiple myeloma cells and decrease myeloma engraftment in a bioluminescent xenograft mouse model. Haematologica. 2012;97(7):1020-8.

Place Hold on Natural killer cell lines preferentially kill clonogenic multiple myeloma cells and decrease myeloma engraftment in a bioluminescent xenograft mouse model

Phenotypic and functional evaluation of CD3+CD4-CD8- T cells in human CD8 immunodeficiency

By Allende Martínez, Luis Miguel | Guerra Vales, Juan Manuel | Mancebo Sierra, Esther | Paz Artal, Estela | Ruiz Contreras, Jesús | Serrano Hernández, Antonio | Talayero Giménez de Azcárate, Paloma . Haematologica, 2011 . 96(8):1195-1203. , Formato Vancouver: Bernardo I, Mancebo E, Aguiló I, Anel A, Allende LM, Guerra-Vales JM, et al. Phenotypic and functional evaluation of CD3+CD4-CD8- T cells in human CD8 immunodeficiency. Haematologica. 2011;96(8):1195-203.

Place Hold on Phenotypic and functional evaluation of CD3+CD4-CD8- T cells in human CD8 immunodeficiency

Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy

By Ayala Díaz, Rosa María. Haematologica, 2011 . 96(10):1470-1477. , Formato Vancouver: Barragán E, Montesinos P, Camos M, González M, Calasanz MJ, Román-Gómez J, et al. Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy. Haematologica. 2011;96(10):1470-7.

Place Hold on Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy